Cover Image
市場調查報告書

全球乳癌市場

Global Breast Cancer Market Report: 2015 Edition

出版商 Koncept Analytics 商品編碼 204467
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
全球乳癌市場 Global Breast Cancer Market Report: 2015 Edition
出版日期: 2015年08月11日 內容資訊: 英文 64 Pages
簡介

乳癌,是最常診斷出的癌症,是女性癌症的死亡原因的第1名。乳癌最常見的危險因素,是女性和老齡化。

本報告提供全球乳癌診斷、治療市場相關調查分析,以美國、巴西、歐洲、亞太地區為焦點,提供市場動態,成長推動因素與課題、競爭情形、主要企業等相關的系統性資訊。

第1章 市場概要

  • 乳癌
  • 乳癌的種類
  • 危險因素
  • 乳癌的症狀
  • 乳癌的診斷和治療
    • 乳癌的檢驗、診斷法
    • 乳癌的治療方法

第2章 乳癌市場

  • 全球市場
    • 診斷市場
    • 治療市場
    • 市場區隔

第3章 地區市場

  • 美國
  • 巴西
  • 亞太地區
  • 歐洲

第4章 市場動態

  • 產業的發展
  • 成長推動因素
  • 課題

第5章 競爭情形

  • 醫藥品比較
  • 淨利
  • R&D預算

第6章 企業簡介

  • 產業概要、財務概要、產業策略
    • Johnson & Johnson
    • Hologic, Inc.
    • Roche
    • Novartis
    • Siemens AG

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women. Breast cancer knows no boundaries be it age, gender, socioeconomic status or geographic location. The most common risk factors for breast cancer are being female and growing older.

In the past few years, the cases of breast cancer have increased tremendously in regions like the US and the Europe. The breast cancer market is driven by various factors like aging female population, obesity and diabetes, dense breast tissues, healthcare expenditure, exposure to X-Ray and Gamma Radiations, Estrogen-Progestin Therapy (EPT) and increased consumption of alcohol and tobacco. A major trend which will probably remain eternally in the breast cancer treatment industry is the fact that novel and innovative technologies and pharmaceutical molecules are always under development. Challenges associated with breast cancer are like, financial burdens associated with the treatment and adverse effects of Aromatase Inhibitors (AI) on patients.

The market for breast cancer drugs represents an area of potential opportunity in both developed and developing countries. Due to effectiveness and advancements in technology, a large number of companies are focusing to develop innovative breast cancer drugs. Further, the companies are forming alliances and agreements to develop effective treatment methods for breast cancer.

The present report provides a comprehensive analysis of the global breast cancer diagnosis and treatment market with focus on regions like the US, Brazil, Europe and APAC Countries. Furthermore, market dynamics such as the industry trends and development, the underlying growth drivers and major issues faced by the industry are elicited. On the contention front, the market is personified by the intense competition in terms of research and development of novel therapeutic molecules. The leading players operating in the industry include Hologic, Johnson and Johnson, Siemens AG, Roche and Novartis which are also profiled in this report.

Table of Contents

1. Market Overview

  • 1.1. Breast Cancer
  • 1.2. Types of Breast Cancer
  • 1.3. Risk Factors
  • 1.4. Symptoms of Breast Cancer
  • 1.5. Diagnosis and Treatment of Breast Cancer
    • 1.5.1. Breast Cancer Screening and Diagnostic Measures
    • 1.5.2. Breast Cancer Treatment

2. Breast Cancer Market

  • 2.1. Global Market
    • Diagnostics Market
    • Therapeutic Market
    • Market Segmentation

3. Regional Markets

  • 3.1. The U.S. Breast Cancer Market
    • 3.1.1. The U.S. Breast Cancer Diagnostics Market
    • 3.1.2. The U.S. Breast Cancer Therapeutic Market
    • 3.1.3. The U.S. Metastatic Breast Cancer Market
  • 3.2. Brazilian Breast Cancer Market
    • 3.2.1. Brazilian Breast Cancer Diagnostic Market
    • 3.2.2. Brazilian Breast Cancer Therapeutic Market
  • 3.3. APAC Countries
    • 3.3.1. APAC Diagnostic Market
    • 3.3.2. APAC Therapeutic Market
  • 3.4. European Breast Cancer Market
    • 3.4.1. European Breast Cancer Diagnostic Market
    • 3.4.2. European Metastatic Breast Cancer Market

4. Market Dynamics

  • 4.1. Industry Developments
    • 4.1.1. Introduction of New Drugs & Therapies
    • 4.1.2. Development of Scintimammography for Molecular Breast Imaging
    • 4.1.3. Compounds under Study to Reduce Breast Cancer
    • 4.1.4. Researches on DCIS Prediction
  • 4.2. Growth Drivers
    • 4.2.1. Increasing Use of Tobacco and Alcohol
    • 4.2.2. Increasing Diabetic and Obese Population Worldwide
    • 4.2.3. Rising Healthcare Expenditure
    • 4.2.4. Growing Women Population (Over 45 Years)
    • 4.2.5. Increasing Global Spending on Medicines
    • 4.2.6. Dense Breast Tissue
    • 4.2.7. Exposure to X-Ray and Gamma Radiations
    • 4.2.8. Estrogen-Progestin Therapy (EPT)
  • 4.3. Challenges
    • 4.3.1. Financial Burden of Breast Cancer
    • 4.3.2. Adverse Effects of Aromatase Inhibitors (AI)

5. Competitive Landscape

  • Comparison of Drugs
  • Net Income
  • R&D Budget

6. Company Profiles

  • 6.1. Johnson & Johnson
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. Hologic, Inc.
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. Roche
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. Novartis
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies
  • 6.5. Siemens AG
    • 6.5.1. Business Overview
    • 6.5.2. Financial Overview
    • 6.5.3. Business Strategies

List of Charts

  • Types of Breast Cancer
  • Various Biopsy Methods
  • Global Oncology Drug Spending (2010-2014)
  • Global Oncology Spending By Region (2014)
  • Global Breast Cancer Predictive Diagnostic and Drug Technologies (2014 /2019E)
  • Global Breast Cancer Therapeutic Market (2014 /2018E)
  • Global Breast Cancer Market by Segments (2014E)
  • Cases of Breast Cancer in the U.S. by Stage
  • Breast Cancer Deaths by Age Group in the U.S.
  • The U.S. Breast Imaging Systems Market (2010-2016E)
  • The U.S. Digital Mammography Market (2010-2014)
  • Breast Cancer Therapeutic Market in Major Regions (2014E)
  • The U.S. Metastatic Breast Cancer Market Revenues (2011-2015E)
  • Breast Cancer Mortality Rates in Brazil (2008-2014E)
  • Brazil's Breast Cancer Imaging Market (2011-2015E)
  • Brazilian Breast Cancer Drugs Market (2009-2014E)
  • APAC - Tomography Scanners per Million People (2014)
  • APAC - MRI Units per Million People (2014)
  • APAC - Mammography Units per Million Females (2014)
  • APAC Countries Therapeutic Market Share (2014E)
  • The European Breast Imaging Systems Market (2013-2018E)
  • The European Mammography Systems Market (2013-2018E)
  • European Metastatic Breast Cancer Market Revenues (2011-2015E)
  • Global Cigarettes Consumption (1910-2014)
  • Global Diabetic Population (2007-2014E)
  • Global Obese Population (2009-2014)
  • Global Healthcare Expenditure Per Capita (2009-2014E)
  • Global Female Population, Over 45 Years (2008-2014E)
  • Global Spending on Medicines (2007-2017E)
  • Net Income Comparison of Leading Companies (2014)
  • R&D Budgets of Top Companies (2014)
  • Johnson & Johnson Revenue by Business Segments (2014)
  • Johnson & Johnson's Revenue and Net Income (2010-2014)
  • Hologic's Revenue by Business Segment (2014)
  • Hologic's Revenue and Net Income (2010-2014)
  • Roche's Revenue by Business Segments (2014)
  • Roche's Sales and Net Income (2010-2014)
  • Novartis Revenue by Business Segments (2014)
  • Novartis Revenues (2010-2014)
  • Siemens Revenue by Business Segments (2014)
  • Siemens Revenue and Net Income (2010-2014)

List of Tables

  • Stages of Breast Cancer
  • New Breast Cancer Cases and Deaths in the U.S. (2015E)
  • The U.S. MBC Market Revenue Model (2011-2015E)
  • Number of Deaths from Breast Cancer in Brazil
  • New Breast Cancer Cases and Deaths in the Europe (2014)
  • European MBC Market (2011-2015E)
  • CDK4/6 Inhibitors in Clinical Development
  • Side Effects of Aromatase Inhibitors Reported by Women
  • Comparison of Drugs Approved for HR Positive Breast Cancer
  • Comparison of P13 Kinases in Clinical Development
  • J&J's R&D Expenses by Segment (2013 & 2014)
Back to Top